{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"32","value":"39.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37","value":"68.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"}],"units":"Participants"}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32","value":"85.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"title":"Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31","value":"99.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"title":"Cycle 14"}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"}],"units":"Participants"}],"description":"Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Part B: 10 mg/kg ramucirumab every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Part B: Ramucirumab+ Erlotinib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Part B participants who received at least one dose of Ramucirumab+ Erlotinib who had evaluable PK data. Per protocol, Part A did not evaluate PK.","reportingStatus":"POSTED","timeFrame":"Cycle 2 Day 1: Predose; Cycle 4 Day 1: Predose; Cycle 7 Day 1: Predose; Cycle 14 Day 1","title":"Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab","type":"SECONDARY","unitOfMeasure":"microgram per milliliter (µg/mL)"}